Julie Kanter, MD

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Julie Kanter, MD, is the codirector of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham, where she is also a professor in the divisions of hematology and oncology.

Articles by Julie Kanter, MD

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 25th 2026

Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion.

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 19th 2026

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

EHA 2026 Congress recap | Image Credit: Brooke McCormick

Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

ByBrooke McCormick,Nitin Jain, MD,Irina Murakhovskaya, MD,Rahul Banerjee, MD,Julie Kanter, MD

June 18th 2026

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Julie Kanter, MD

Articles by Julie Kanter, MD

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

Latest Updated Articles

Trending on AJMC

340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs

FDA Approves Atacicept for IgA Nephropathy

Ebola Cases Top 1700 as Unpaid Health Workers Strike

Quest Adds Haystack MRD to OncoEMR for Community Oncology

IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Julie Kanter, MD

Articles by Julie Kanter, MD

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

Latest Updated Articles

Trending on AJMC

340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs

FDA Approves Atacicept for IgA Nephropathy

Ebola Cases Top 1700 as Unpaid Health Workers Strike

Quest Adds Haystack MRD to OncoEMR for Community Oncology

IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk